SCHEMBL14701528

SCHEMBL14701528

CCC(=O)NC(CC)c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
LMNA P02545 4/20 0.59
KDM4E B2RXH2 1/20 0.59
HPGD P15428 1/20 0.59
TSHR P16473 1/20 0.59
HSD17B10 Q99714 1/20 0.59
POLB P06746 1/20 0.57
SLC6A9 P48067 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.54
EPHX2 P34913 2/20 0.54
TAOK1 Q7L7X3 1/20 0.53
TAOK3 Q9H2K8 1/20 0.53
KCNA5 P22460 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
HTT P42858 1/20 0.50
NCOA1 Q15788 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
PARP1 P09874 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14535420 1.00 ALDH1A1 (0.59) ALDH1A1LMNAKDM4EHPGDTSHR
SCHEMBL14224491 0.87 RIPK1 (0.62) ALDH1A1LMNAPOLBSMN1; SMN2EPHX2
SCHEMBL6857593 0.87 SMN1; SMN2 (0.64) ALDH1A1LMNAPOLBSMN1; SMN2HTT
SCHEMBL14224547 0.87 RIPK1 (0.62) ALDH1A1LMNAPOLBSMN1; SMN2EPHX2
SCHEMBL13947719 0.86 ALDH1A1 (0.56) ALDH1A1LMNAKDM4EHPGDTSHR
SCHEMBL3370482 0.85 ALDH1A1 (0.63) ALDH1A1LMNAKDM4EHPGDTSHR
SCHEMBL15093820 0.85 EPHX2 (0.65) ALDH1A1LMNAKDM4EHPGDTSHR
SCHEMBL2022347 0.85 ALDH1A1 (0.63) ALDH1A1LMNAKDM4EHPGDTSHR
SCHEMBL3376152 0.85 ALDH1A1 (0.63) ALDH1A1LMNAKDM4EHPGDTSHR
SCHEMBL16901651 0.84 ROCK1 (0.51) ALDH1A1LMNAKDM4EHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9616064-B2 Rho kinase inhibitors and methods of use H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2017-04-11 US disclosed
CN-106324153-A Method for measuring content and optical purity of amino acid-N-formic anhydride 深圳翰宇药业股份有限公司 2017-01-11 CN disclosed
US-8809338-B2 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) 2014-08-19 US disclosed
US-20130040964-A1 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) 2013-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040964-A1 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS ICAM1, ITGB3, VCAM1 ALDH1A1 368/4885LMNA 4608/4885KDM4E 3844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.